Oramed Pharmaceuticals, Inc
ORMP
Get informed when a big investor buys or sells
+ FollowMarket Cap$205.86M
Close$
$0.98
80.1% downside
Current Fair Value
80.1% downsideOvervalued by 80.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $205.86 Million |
|---|---|
| Enterprise Value | $193.06 Million |
| Dividend Yield | $0.25 (4.97%) |
| Earnings per Share | $1.53 |
| Beta | 1.16 |
| Outstanding Shares | 41,040,479 |
Return
| Return on Equity | 58.63% |
|---|---|
| Return on Assets | 58.86% |
| Return on Invested Capital | 25.49% |
Valuation & Multiples
| P/E Ratio | 1.19 |
|---|---|
| PEG | 0.24 |
| Price to Sales | - |
| Price to Book Ratio | 0.82 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 2.48 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$0.15
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$0.43
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 32.47%▲ 0.94% |
|---|---|
| Total Invested | $45.02M▲ 20.96% |
| Investors Holding | 64▲ 7.00% |
ESG Score
No data
About Oramed Pharmaceuticals, Inc
CEO: Nadav Kidron